The team developed a tumor-independent test that is used to evaluate genome-wide cell-free DNA fragmentation profiles and repeat landscapes.

The firm touted new assays, provided an update on its nanopore sequencer, and offered insights into upcoming pipeline ...

The firm raised its full-year revenue guidance on expectations of growth in the range of 3 to 5 percent but it maintained its full-year EPS guidance.

The firm's shares rose to $62.17 at the close of Tuesday's trading on news that TPG and Blackstone had offered to take the firm private.

According to the FDA, the tubes are not being produced in conformity with good manufacturing practice and have led to false positive lead test results.

Investors and consultants in the space said that they have seen rising enthusiasm among investors as recent funding rounds ...

Last week, readers were most interested in a story about an MOU between Gene Solutions and NEWCL to establish a lab in Taiwan.

During a fireside chat at the RBC Healthcare Conference, Bio-Rad's CFO Roop Lakkaraju confirmed the firm's prior guide for 130 basis points of net tariff impact, which Connor McNamera, RBC's moderator ...

The firm presented data at AACR that showed the test had high accuracy when distinguishing ovarian cancer at early stages.

An unnamed party has made a bid to acquire Akoya at a price of $1.40 per share, which Akoya said could prove a superior proposal to its planned merger with Quanterix.

The lateral flow, fingerprick blood test measures monoclonal proteins, with results that can be read on a phone app.

Tempus' FDA-approved xT CDx test is being used as an investigational assay in Verastem's global Phase 3 RAMP-301 clinical trial.